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A B S T R A C T   
Background: Disorders of mental health are major risk factors for suicidal behavior and require adequate treat-
ment. However, the effect of psychotropic medication on suicidal behavior is unclear. 
Methods: The 120 participants in a randomized clinical trial of a brief therapy for suicide attempters (Attempted 
Suicide Short Intervention Program, ASSIP) reported on repeated suicide attempts, suicidal ideation, depression, 
and medication in the treatment as usual (TAU), at baseline, 6, 12, 18, and 24 months follow-up. The RCT had no 
influence on medication prescribed. Drugs prescribed were categorized as any psychotropic, antidepressants plus 
lithium, and antipsychotics. To assess the effect of long-term medication we identified participants with periods 
of continuous use of psychotropics and antidepressants plus lithium over twelve months or more, and 
medication-free participants for the same drug categories during the same time period. 
Results: Reattempts and suicide ideation decreased in all drug categories. When comparing participants on 
medication fulfilling the definition of long-term use with participants without medication, reattempts and sui-
cidal ideation were higher in the psychotropics and the antidepressants/lithium groups. These drug categories 
were associated with higher depression scores in comparison to no-medication. The survival analysis revealed a 
higher risk of reattempts in the long-term antidepressants/lithium group in comparison to no-medication. 
Treatment with the brief psychological therapy ASSIP, added to medication, was associated with a lower risk 
of reattempts. 
Limitations: The study relied on the patients’ reports on treatment as usual in a randomized controlled clinical 
trial. Blood levels of the psychotropic compounds were not assessed. 
Conclusions: In this observational study of the TAU condition in a clinical trial of a brief psychological therapy for 
patients who had recently attempted suicide, psychotropic drug use over twelve months or more was not 
associated with reduced suicide ideation and reattempts. Depression scores suggest that patients on psychotropic 
medication had more psychiatric pathology. This may be a confounding factor for the effect of medication on 
suicidal behavior.   
1. Introduction 
Approximately 800,000 people die by suicide each year, and the 
number of suicide attempts may be more than twenty times higher 
(World Health Organization, 2012; Naghavi, 2019). There is an inter-
relation between suicide ideation and suicidal behavior (Kessler et al., 
2005). Bertolote, Fleischmann (Bertolote et al., 2005) reported a 13.5% 
prevalence of suicide ideation and a 4.6% lifetime prevalence of 
attempted suicide in the general population. 
Patients who attempt suicide usually enter the medical system 
through admission to general and psychiatric institutions, where ther-
apeutic interventions can be implemented, and, if indicated, psycho-
pharmacological treatment installed. The effect of treatment on suicidal 
behavior is of special interest in these patients, considering that 
attempted suicide is the main risk factor for suicide (Suokas et al., 2001; 
Ribeiro et al., 2016; Bostwick and Pankratz, 2000), especially when 
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characterized by hopelessness and high intent (Suominen et al., 2004). 
Gibb and Beautrais (2004) reported that within 10 years 28.1% of pa-
tients admitted after a suicide attempt made reattempts, and 4.6% died 
by suicide. Importantly, the risk of death by suicide in the first year after 
attempted suicide is much higher in patients with mood disorders 
(Bostwick and Pankratz, 2000; Nordstrom et al., 1995). 
Of special interest is the question if pharmacotherapy for patients 
who attempt suicide can reduce the frequency of suicide reattempts and 
suicide. Between 56 and 87% of suicide victims suffer from major 
depressive disorders (Bostwick and Pankratz, 2000; Coryell and Young, 
2005), however, the evidence for the effect of antidepressant treatment 
on suicide is controversial (Van Praag, 2003; Simon et al., 2006). For 
instance, Leon, Keller (Leon et al., 1999) reported that treatment with 
Fluoxetine was associated with a decrease of suicidal behavior. Others 
found that the use of antidepressants was associated with a lower risk of 
completed suicide, while the risk of attempted suicide increased (Tii-
honen et al., 2006). Stone, Laughren (Stone et al., 2009) in a 
meta-analysis of randomized controlled trials found an age-dependent 
effect of antidepressants on suicidal behavior, with an increased risk 
in participants aged below 25 and a protective effect for adults above 65. 
Olfson, Marcus (Olfson et al., 2006) similarly reported an association 
between antidepressant drug treatment in adolescents but not in adults. 
A meta-analysis of 29 placebo-controlled studies concluded that the 
incidence rates of suicide and suicide attempts were higher among pa-
tients treated with antidepressants compared to placebo (Braun et al., 
2016). In the active drug arms suicides occurred 5 times more often and 
the risk of suicide attempts was 9-fold. Yerevanian, Koek (Yerevanian 
et al., 2004) compared the rates of suicidal behavior in 521 unipolar 
depressed patients during, and after discontinuation of long-term anti-
depressant (SSRIs and TCAs) pharmacotherapy. Suicidal behavior 
increased substantially after medication discontinuation. There is good 
evidence for the antisuicidal properties of lithium in long-term treat-
ment. A meta-analysis of RCTs in unipolar and bipolar disorders showed 
that lithium significantly reduces suicide compared with placebo 
(Cipriani et al., 2013). Furthermore, long-term treatment with the 
antipsychotic drug clozapine, compared with other antipsychotics, has 
been associated with a reduced incidence of suicidal behavior (Hennen 
and Baldessarini, 2005). 
In view of the long-term elevation of suicide risk in people with a 
history of attempted suicide, the effect of long-term pharmacotherapy is 
a particular focus of interest. Angst, Stassen (Angst et al., 2002) followed 
406 formerly hospitalized patients with unipolar and bipolar depression 
over 22 years or more. Patients on psychotropic medication (antide-
pressants, antipsychotics, and/or lithium) had a significantly lower 
suicide mortality compared to untreated patients. The minimal duration 
of pharmacotherapy was 6 months, but the precise length of treatment 
was not determined. Leon, Fiedorowicz (Leon et al., 2014) in a 27-year 
observational follow-up study involving 706 patients found a significant 
effect of antidepressant medication on suicidal behavior, with a risk 
reduction of 54% for bipolar I disorder and 35% for bipolar II disorder, 
but no effect for unipolar depression. Length of antidepressant exposure 
was defined as the number of consecutive weeks of antidepressant 
medication until suicidal behavior. Intervals of exposure were compared 
with intervals of nonexposure. 
With detailed 24-months follow-up information on treatment as 
usual, including psychotropic drug treatment, the participants of the 
ASSIP RCT (Gysin-Maillart et al., 2016) represented an ideal population 
to investigate the relationship between psychotropic drug treatment and 
suicide reattempts and suicidal ideation in a naturalistic clinical setting. 
We hypothesized that long-term psychopharmacological treatment, here 
defined as the use of psychotropic drugs over more than 12 months, 
would be associated with reduced suicidal behavior. 
2. Materials and methods 
The study is part of the ASSIP effectiveness trial published elsewhere 
(Gysin-Maillart et al., 2016). ASSIP is an add-on therapy, administered 
in addition to the usual clinical treatment (TAU), which included 
inpatient or outpatient care, any form of psychotherapy, and pharma-
cotherapy. In this study a total of 120 patients who had recently 
attempted suicide were randomly assigned to ASSIP therapy (60) or the 
control group (60). Exclusion criteria were habitual self-injury, severe 
cognitive impairment and psychotic disorders. Current suicide risk was 
not an exclusion criterion, that is, the trial included patients with high 
suicide risk. Psychiatric diagnoses at baseline were based on the hospital 
records. Sixty-three percent of participants were diagnosed with affec-
tive disorders. The ASSIP treatment group received three one-to-one 
manual-based therapy sessions followed by regular outreach contact 
through semi-standardized letters over 24 months in addition to treat-
ment as usual (TAU). The control group received a single suicide 
assessment interview, in addition to TAU. 
The present study is a secondary analysis of data on medication as 
part of TAU. The clinical trial of ASSIP had no influence on medication 
prescribed in TAU. Information on drug use was collected through 
questionnaires sent to study participants every 6 months during the 24 
months follow-up. Patients were asked to report trade names of all 
prescribed drugs and the exact dosages. For analysis, drugs were clas-
sified as (1) any psychotropic drug, with the subgroups of (2) antide-
pressants, (3) lithium, and (4) antipsychotics (Zohar et al., 2015). These 
are the drug categories with some evidence of effectiveness in pre-
venting suicidal behavior (Hennen and Baldessarini, 2005; Leon et al., 
2014). Because of the small number of patients on lithium (n = 5), an-
tidepressants and lithium were combined as one group (AD/Li). Similar 
to the Angst et al. (2002) study, pharmacotherapy was classified as 
long-term, when the same class of drug was taken over a time period of 
12 months or more. We therefore identified participants with contin-
uous use of the same drug category over three or more timepoints within 
the 24-months follow-up. Similarly, we identified participants who over 
three consecutive timepoints reported that they were not using any of 
these drugs. As the three-timepoint periods could be anywhere between 
t1 and t5, the definition included participants without medication at 
baseline but starting on drugs later during follow-up. 
The 21-item Beck Depression Inventory (BDI) was used to measure 
the severity of depression (Beck and Steer, 1987; Hautzinger et al., 
1994). The Beck Scale for Suicide Ideation (BSS) was used to measure 
the intensity of the patients’ suicidal ideation (Beck and Steer, 1991). 
The BSS consists of 21 items and is a self-report instrument to assess the 
intensity of the patient’s attitudes, behaviors, and plans related to sui-
cidal behavior during the past week, including the current day, with 
item scores ranging from 0 to 2. Three additional questions referred to 
suicidal behavior and differentiated between non-suicidal self-harm and 
suicide attempts. The German definition of attempted suicide is similar 
to the use in the US and the Silverman criteria (Silverman et al., 2007), 
which require the presence of intent to die. The total number of reat-
tempts in the clinical trial was 46 (ASSIP group: n = 5, control group n =
41). 
2.1. Statistics 
Descriptive statistics were used for baseline measures at t1 (time of first 
interview with study participants after the suicide attempt). For the 
calculation of suicide reattempts and of suicidal ideation for all drug 
groups (antidepressants/lithium, antipsychotic, and psychotropic) across 
all timepoints (baseline, 6 months, 12 months, 18 months, and 24 months) 
linear mixed effect models were used by means of the lmer function from 
the lme4 package (Bates et al., 2015). The numbers of suicide attempts at 
t1 were reduced by 1, because t1 included the index attempt leading to 
referral. We then analyzed reattempts and suicidal ideation in relation to 
the medication taken over three or more consecutive timepoints vs 
no-medication for the same time period. BDI was added to the models as a 
covariate for suicide ideation. The survival probability and hazard ratio 
were calculated for each group of medication vs. no-medication, using the 
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Kaplan-Meier estimate and the coxph function respectively, by means of 
the survival package in R (Therneau, 2020). Furthermore, we included the 
two arms (ASSIP, Control) of the original clinical trial in the survival 
analysis, which resulted in a total of four groups (medi-
cation/intervention, medication/control, no-medication/intervention, 
and no-medication/control). 
3. Results 
Baseline data at t1 (Table 1) were collected from the first interview 
with participants of the ASSIP clinical trial (N = 120). Seventy-seven 
participants were on psychotropic drugs, 20 of those were taking anti-
psychotics, and 74 were taking antidepressants or lithium, 43 had no 
medication at baseline. Participants on medication had more diagnoses 
of mood disorders, more previous suicide attempts, and more suicidal 
ideation at baseline. 
Focusing on participants who fulfilled the definition of long-term 
medication at any time period within the 24-months follow-up period 
reduced the number of participants to 56 for the psychotropic group, to 
14 for the antipsychotic, and to 28 for the antidepressant/lithium group 
(AD/Li). The main substances prescribed long-term according to this 
definition are listed in Table 2. With the small number of participants on 
antipsychotics we decided to continue the further analysis without this 
group. Antidepressants were frequently combined (12/28), and all 
participants on lithium were co-medicated with antidepressants. With 
very few exceptions, the daily doses were considered to be adequate (e. 
g. amitriptyline 200 mg, paroxetine 40 mg, fluvoxamine 200 mg, 
duloxetine 120 mg). 
Table 3 shows the clinical measures across time-points for partici-
pants using any psychotropic, and the AD/Li category as long-term 
medication, and for those with no long-term medication of the same 
category. These findings are presented graphically in Figs. 1 and 2. 
We then compared the long-term use of any psychotropic (n = 56) 
with no psychotropic medication over the same time period (n = 27). 
Suicide reattempts decreased in both groups (F4, 248 = 3.1; p = 0.01; 
Fig. 1a), with no significant group difference (F1, 85 = 0.9; p = 0.34). No 
significant interaction between group x timepoint was observed (F4, 248 
= 1.0; p = 0.41). Suicidal ideation (BSS) decreased in both groups, with 
higher scores in the psychotropic group (Fig. 1b). No significant differ-
ences in timepoint, group, or group x timepoint interaction were found 
(all F < 1.9; p > 0.16). BDI scores decreased in both groups over time (F4, 
228 = 20.1; p < 0.0001), but they were higher in the psychotropics group 
(F1, 74 = 4.2; p = 0.04). BDI correlated with the BSS (rho>0.43; p <
0.05) and had a significant effect on suicide ideation (F1, 291 = 142.3; p 
> 0.0001). 
A similar picture emerged in the comparison of long-term AD/Li use 
(n = 28) with no AD/Li medication (n = 35). Suicide reattempts 
decreased in both groups, with no significant difference (F1, 61 =2.5; p =
0.11; Fig. 2a), and no significant interaction between group x timepoint 
(F4, 241 = 1.1; p = 0.33). BSS scores decreased in both groups (F4, 187 =
2.8; p = 0.02; Fig. 2b), but were higher in the medication group (F1, 61 =
5.1; p = 0.02). BDI scores decreased in both groups (F4, 189 = 22.1; p <
0.0001), but were higher in the medication group (F1, 58 = 7.1; p =
0.01). BDI scores correlated with the BSS (rho >0.35; p < 0.05), and had 
a significant effect on suicide ideation (F1, 235 = 43.5; p > 0.0001). 
The reattempt-free survival probability for long-term use of psy-
chotropics vs no psychotropics showed a significant difference, with 
more reattempts in the medication group (HR = 0.198, p = 0.03, 
Kaplan–Meier survival curves, Fig. 3). For AD/Li vs no AD/Li a decrease 
of reattempts in both groups was found, with a trend to lower survival 
probability (i.e. more suicide attempts) in the medication group (HR =
0.373, p = 0.07). 
Finally, we related the medication use to the ASSIP/Control condi-
tions from the original clinical trial. Fig. 4 shows the Kaplan–Meier 
survival curves for suicide reattempts related to long-term medication. 
Use of any psychotropic drug plus ASSIP treatment was associated with a 
significantly better outcome (HR = 3.853, p = 0.004). A similar pattern 
was found for antidepressants/lithium at trend level (HR = 2.053, p =
Table 1 
Demographic and clinical characteristics at baseline.   
Any Psychotropic (n = 77) Antipsychotics (n = 20) Antidepressants/lithium (n = 74) No Medication (n = 43) One-way Anova (F; p-value) 
Demographic 
Age (mean ± SD years) 39.3 ± 12.8 37.2 ± 11.2 38.7 ± 12.2 34.1 ± 16.0 F3, 198 = 1.53; 0.30 
Gender (females %) 55.8% 73.7% 51.6% 51.0% F3, 198 = 0.97; 0.40 
Diagnosis (ICD-10%) 
F1 19.4 15 12.2 35.7  
F3 75.3 55 72.9 33.3  
F4 29.8 50 22.9 69.0  
F6 18.1 20 17.5 11.9  
Other 7.7 5 8.1 4.7  
Previous suicide attempts (%) 
0 39.0 47.4 36 69.0  
1 28.6 21.0 31.2 14.3  
2 or more 32.4 31.6 32.8 16.7  
Assessments (mean ± SD)      
BSS 0.49 ± 0.47 0.51 ± 0.51 0.56 ± 0.52 0.30 ± 0.40 F3, 196¼2.63; 0.05 
BDI 19.8 ± 9.6 19.6 ± 12.6 20.0 ± 13.2 15.3 ± 9.6 F3, 195¼1.55; 0.20 
BSS: Beck Scale for Suicide Ideation; BDI: Beck Depression Inventory; ICD-10: International Classification of Diseases; F1: Substance abuse disorder; F3: Mood disorder; 
F4: Neurotic, stress-related and somatoform disorders; F6: Disorders of adult personality and behavior. The “Any Psychotropic” category includes patients on any 
psychopharmacological substance. Thus, subjects in the antipsychotic or antidepressant/lithium group are included in the psychotropic group but may overlap. 
Table 2 
Most frequent substances prescribed long-term (>12 months).  
Drug group # of cases Dosage range (mg) 
Antidepressants/lithium 28  
Amitriptyline 5 125–200 
Clomipramine 2 37.5–300 
Trimipramine 3 10–25 
Venlafaxine 5 75–300 
Mirtazapine 3 30–45 
Duloxetine 3 60–120 
Trazodone 3 50–300 
Paroxetine 2 40 
Escitalopram 3 10–30 
Lithium 5 225–1325 
Antipsychotics 14  
Quetiapine* 11 100–1000 
Olanzapine 2 5 
Clotiapine 1 20  
* In 9/11 participants quetiapine was prescribed as co-medication with anti-
depressants, and one participant was taking quetiapine 1000 mg + valproate.  
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The results of this observational study (Grimes and Schulz, 2002) are 
based on the 24 months follow-up data collected from the participants of 
a previously published clinical trial with 120 individuals who had 
attempted suicide. The randomized controlled clinical trial investigated 
the effectiveness of ASSIP, a brief, structured therapy on reducing sui-
cidal behavior, designed as add-on therapy to treatment as usual. The 
trial had no influence on treatment as usual. During follow-up over two 
years, patients filled in questionnaires in six-monthly intervals, which 
included questions about suicide reattempts and suicidal ideation, 
depression (BDI), suicidal ideation (BSS). Questions on treatment as 
usual included outpatient or inpatient treatment, and medication, with 
daily doses. 
In the 24 months follow-up of TAU, suicide reattempts and suicidal 
ideation (measured by the BSS) decreased for the any psychotropic 
group as well as for the antidepressant plus lithium group. In the samples 
of participants on medication over at least 12 months and the respective 
no-medication samples, suicide reattempts and suicidal ideation 
decreased in the medication groups and in the no-medication groups. 
However, medication was associated with more suicidal ideation, with 
the difference reaching statistical significance in the antidepressant/ 
lithium group. The medication groups recorded more suicide reattempts 
over 24 months. In the survival analysis we found a lower survival 
probability for reattempts in the antidepressants/lithium group 
compared to the corresponding no-medication group (HR = 0.373). 
Depression scores were higher in the long-term medication groups, 
although they decreased over time in both groups. The depression scores 
suggest that participants in the medication group had more psychopa-
thology and were therefore more likely to use medication over 12 
months or more. Furthermore, in our analysis, BDI was a strong pre-
dictor for suicide ideation (but not for attempts). This is not surprising, 
considering the positive correlation between the BDI and the Beck scale 
for suicide ideation (Beck et al., 1979). 
Finally, when investigating the effect of the brief psychological 
therapy ASSIP on participants taking long-term medication, we found 
Table 3 
Clinical measures (mean ± SD for each group) across time-points for participants on long-term medication/no-medication (= more than three timepoints on the same 
drug category within the 24-months follow-up).   
Any psychotropic (n = 56) No psychotropic (n = 27) Antidepressants/lithium (n = 28) No Antidepressant/Lithium (n = 35) 
Suicide Attempts 
Baseline 0.38 ± 0.82 0.37 ± 1.01 0.44 ± 0.93 0.36 ± 0.96 
6 months 0.27 ± 0.90 0.00 ± 0.00 0.42 ± 1.02 0.00 ± 0.00 
12 months 0.02 ± 0.16 0.13 ± 0.51 0.10 ± 0.44 0.09 ± 0.44 
18 months 0.14 ± 0.55 0.00 ± 0.00 0.21 ± 0.71 0.08 ± 0.29 
24 months 0.21 ± 0.68 0.00 ± 0.00 0.21 ± 0.78 0.00 ± 0.00 
BSS scores 
Baseline 0.50 ± 0.52 0.29 ± 0.42 0.58 ± 0.57 0.29 ± 0.41 
6 months 0.36 ± 0.50 0.23 ± 0.33 0.46 ± 0.57 0.22 ± 0.31 
12 months 0.33 ± 0.44 0.09 ± 0.30 0.34 ± 0.48 0.06 ± 0.25 
18 months 0.32 ± 0.46 0.10 ± 0.18 0.36 ± 0.52 0.12 ± 0.20 
24 months 0.21 ± 0.38 0.04 ± 0.12 0.24 ± 0.40 0.03 ± 0.11 
BDI scores 
Baseline 19.7 ± 11.4 15.4 ± 9.60 21.3 ± 10.7 14.7 ± 9.73 
6months 14.8 ± 11.7 11.9 ± 9.40 16.1 ± 11.7 10.5 ± 9.20 
12 months 13.3 ± 10.4 7.20 ± 7.34 14.8 ± 11.1 5.95 ± 6.70 
18 months 13.4 ± 13.0 9.62 ± 11.1 13.3 ± 12.7 10.3 ± 10.7 
24 months 9.50 ± 10.1 4.23 ± 5.35 9.25 ± 8.56 4.60 ± 5.27 
BSS: Beck Scale for Suicide Ideation; BDI: Beck Depression Inventory. For suicide attempts and BSS scores see Fig. 1 (a and b), and Fig. 2 (a and b). 
Fig. 1. a) Mean numbers of suicide attempts across timepoints for the long-term use of the any psychotropic group (n = 56, red) and the respective no-medication 
group (n = 27, blue). b) Mean BSS scores for the long-term use of the any psychotropic group (red) and the respective no-medication group (blue). Definition of long- 
term use: medication or no-medication over at least three timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the 
Web version of this article.) 
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Fig. 2. a) Mean numbers of suicide attempts across timepoints for the long-term use of antidepressants/lithium group (n = 28, red) and its respective no-medication 
group (n = 35, blue). Error bars represent standard error of mean. b) Mean BSS scores for the long-term use of the antidepressants/lithium group (red) and the 
respective no-medication group (blue). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 3. a) Kaplan–Meier survival curves for reattempt-free probability by long-term psychotropics (n = 56) vs no medication (n = 27). b) Kaplan–Meier survival 
curves for reattempt-free probability by long-term antidepressants/lithium (n = 28) vs no medication (n = 35). Definition of long-term: medication or no-medication 
over at least three timepoints. 
Fig. 4. a) Kaplan–Meier survival curves for reattempt-free probability by long-term psychotropics and ASSIP (n = 30) vs Control Group (n = 26). b) Kaplan–Meier 
survival curves for reattempt-free probability by long-term antidepressants/lithium and ASSIP (n = 15) vs Control Group (n = 13). 
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that, in comparison to the Control, ASSIP was associated with a signif-
icantly lower number of reattempts, and a similar trend in the antide-
pressant/lithium group. 
We found only one study with a comparable naturalistic follow-up 
design of patients who attempted suicide, that is, a population with a 
high risk of repeated suicidal behavior. Irigoyen et al. (2019) followed 
371 patients who had attempted suicide up over two years. All partici-
pants who reattempted suicide were taking antidepressants, therefore, 
the authors were unable to analyze the association between antide-
pressant medication and suicidal behavior, yet antipsychotics were 
related to more reattempts. Other studies have been based on random-
ized controlled drug trials with patients treated for affective disorders, 
using data on suicidal behavior as adverse events (Braun et al., 2016; 
Cipriani et al., 2013; Carpenter et al., 2011; Gunnell et al., 2005). 
Typically, these studies excluded participants with a suicide risk. 
Our results are in line with reports that found no clear effect of an-
tidepressant treatment on suicidal behavior (Simon et al., 2006; Leon 
et al., 1999; Braun et al., 2016). Similar to our study, Carpenter, Fong 
(Carpenter et al., 2011) found that major depression was associated with 
more suicidal behavior, and with more antidepressant treatment. With 
comparable findings in our observational study, we conclude that pa-
tients on psychotropic medication tend to have more psychiatric pa-
thology and a higher suicide risk, and that this must be taken account of 
in the interpretation of the results. 
4.1. Limitations 
The study has limitations and strengths. The study is a secondary 
analysis, which was not designed to show a difference between psy-
chotropic treatment groups. No blood levels of the prescribed medica-
tions were taken to determine patient compliance. However, a strength 
of the study is that medication was not reported by the prescriber, which 
would leave open the question of patient compliance. Patients reported 
their medication to an independent third party, and in addition, they 
were asked to accurately indicate the daily dosages for each drug. The 
reported dosages were clinically realistic and consistent throughout the 
timepoints. We interpret this as a sign of a satisfactory patient compli-
ance with the prescribed medication. Furthermore, in the vast majority, 
the daily dosages were in the clinically recommended ranges, with a 
tendency to polypharmacy. Because in t1 patients were not specifically 
asked about the date when medication was started, we could not 
determine if medication had been prescribed before, or following the 
index suicide attempt. We therefore excluded t1 from the medication/no 
medication comparison. TAU conditions have been criticized for being 
generally unclear [37]. It is important to note that in the original trial, 
both conditions (ASSIP/Control) were added to treatment as usual, that 
is, TAU was not the control condition. The trial had no influence on TAU, 
which included in- and outpatient treatment settings, and any medica-
tion if indicated. Regarding the survival probabilities related to the 
ASSIP trial conditions it is of interest that the ASSIP treatment group had 
63% fewer days of hospitalization during follow-up. There was no dif-
ference in the numbers of outpatient sessions between ASSIP and 
control. 
5. Conclusions 
In this observational study of medication prescribed in the TAU 
condition to participants in a randomized clinical trial of a brief psy-
chological treatment, the use of psychotropic medication was not asso-
ciated with a decrease of suicidal ideation and suicide reattempts. Study 
participants who were using psychotropic drugs, including antidepres-
sants and lithium, continuously over 12 months or more, reported more 
suicide ideation and more attempts compared to participants on no 
medication. However, as medicated patients had higher depression 
scores, severity of psychiatric pathology may be a confounding factor for 
the effect of medication on suicidal behavior. Interestingly, in an 
additional analysis, a brief psychological therapy (ASSIP), added to 
medication, was associated with a lower number of suicide reattempts. 
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